0001127602-23-024445.txt : 20230919 0001127602-23-024445.hdr.sgml : 20230919 20230919170318 ACCESSION NUMBER: 0001127602-23-024445 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230918 FILED AS OF DATE: 20230919 DATE AS OF CHANGE: 20230919 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nicholson Nur CENTRAL INDEX KEY: 0001827317 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 231264567 MAIL ADDRESS: STREET 1: APELLIS PHARMACEUTICALS, INC. STREET 2: 100 5TH AVENUE, 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 form4.xml PRIMARY DOCUMENT X0508 4 2023-09-18 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001827317 Nicholson Nur C/O APELLIS PHARMACEUTICALS, INC. 100 FIFTH AVENUE, 3RD FLOOR WALTHAM MA 02451 1 Chief Technical Officer 0 Common Stock 2023-09-18 4 M 0 9719 29.76 A 73634 D Common Stock 2023-09-18 4 S 0 9719 42.2085 D 63915 D Common Stock 2023-09-18 4 S 0 10631 46.147 D 53284 D Stock Option (Right to Buy) 29.76 2023-09-18 4 M 0 9719 0 D 2030-08-16 Common Stock 9719 115281 D This transaction was executed in multiple trades at prices ranging from $46.200 - $46.250. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $46.140 - $46.240. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This includes 412 shares from 04/30/2023 ESPP purchase. This stock option was granted on August 17, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service. /s/ David Watson, attorney-in-fact for Nur Nicholson 2023-09-19